Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery -January 26, 2024 at 10:01 am EST

KEYTRUDA doubled median DFS as adjuvant therapy versus observation – 29 months versus 14 months – in these patients


AMBASSADOR /KEYNOTE-123 is the first positive trial for KEYTRUDA as adjuvant...

Related Keywords

Canada ,United States ,American , ,Merck Co Inc ,Alliance For Clinical Trials In Oncology ,Twitter ,Development Agreement ,Statement Of Merck Co Inc ,Merck Research Laboratories ,National Cancer Institute ,Linkedin ,Exchange Commission ,National Clinical Trials Network Groups ,Genitourinary Malignancies Branch ,Facebook ,National Institutes Of Health ,American Society Of Clinical Oncology ,Pfizer ,Youtube ,Instagram ,Clinical Oncology ,Cancers Symposium ,Andrea Apolo ,Bladder Cancer Section ,National Institutes ,Marjorie Green ,Merck Research ,Clinical Trials ,National Clinical Trials Network ,Cooperative Research ,Bacillus Calmette Guerin ,Selected Important Safety ,Important Safety Information ,Fatal Immune Mediated Adverse ,Which Can Present With Diabetic ,Nervous System ,Connective Tissue ,Patients With Multiple ,Neck Squamous Cell ,Mismatch Repair Deficient ,Mismatch Repair Deficient Colorectal ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Markets ,